Opioid Analgesics — MOA & Use

Opioid analgesics work by binding mu receptors in the brain, spinal cord, and peripheral tissues, mimicking endogenous endorphins. Mu-receptor activation produces analgesia, euphoria, sedation, and respiratory depression — all from the same binding event. Full agonists (morphine, hydromorphone, fentanyl, oxycodone) have no ceiling for analgesia; increasing the dose increases the effect, which is why they manage moderate-to-severe pain but carry overdose risk. Mixed agonist-antagonists (butorphanol, nalbuphine) activate kappa receptors while blocking or limiting mu activity, giving them a ceiling effect and making them useful for moderate pain — but they can precipitate withdrawal in a client already on a full agonist. Partial agonists (buprenorphine) bind mu with high affinity but produce submaximal activation, used primarily for opioid use disorder treatment and chronic pain. Morphine remains the gold standard for acute severe pain and is the reference drug for equianalgesic dosing. Fentanyl is 50–100 times more potent than morphine, making it ideal for rapid-onset IV or transdermal use. Hydromorphone is preferred in renal impairment because it produces fewer neurotoxic metabolites than morphine.